550O Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study
R-H. Xu(Sun Yat-sen University), Li Zhang(Fourth Hospital of Changsha), Craig Underhill(AstraZeneca (United Kingdom)), Yanhong Deng(Sun Yat-sen University), Kyung-Woo Lee(Konkuk University), X. Li, Hongming Pan(Sir Run Run Shaw Hospital), Guohong Han(Medical Center Hospital), Ye Xu(Central South University of Forestry and Technology), Suocheng Wei(Minzu University of China), Dongyao Yan(Tucson Medical Center), Pamela N. Münster(University of California, San Francisco), Steve Henderson(University of California, San Francisco), Jing Shan, Dan Ruan(Sun Yat-sen University), Xinxin Xie, Ina Nordman(Calvary Mater Newcastle Hospital), Gary Richardson(Cabrini Hospital)
Cited by 15
Related Papers
A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs
|Cell stem cell|2008|4k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639